Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Diagnostic Medical Systems's EV-to-EBIT or its related term are showing as below:
FRA:DMS1'
s EV-to-EBIT Range Over the Past 10 Years
Min: -36.27 Med: -10.02 Max: 53.54
Current: -21.58
During the past 13 years, the highest EV-to-EBIT of Diagnostic Medical Systems was 53.54. The lowest was -36.27. And the median was -10.02.
FRA:DMS1's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 19.04
vs FRA:DMS1: -21.58
Diagnostic Medical Systems (FRA:DMS1) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Diagnostic Medical Systems's Enterprise Value for the quarter that ended in Dec. 2025 was €42.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diagnostic Medical Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostic Medical Systems EV-to-EBIT Related Terms
Diagnostic Medical Systems EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Diagnostic Medical Systems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostic Medical Systems EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Diagnostic Medical Systems's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Diagnostic Medical Systems's EV-to-EBIT falls into.
Diagnostic Medical Systems's current Enterprise Value is €40.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diagnostic Medical Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostic Medical Systems (FRA:DMS1) has a EV-to-EBIT of -21.58 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diagnostic Medical Systems and its competitors. According to the industry distribution chart, Diagnostic Medical Systems ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Diagnostic Medical Systems' EV-to-EBIT too high?
Diagnostic Medical Systems' current EV-to-EBIT is -21.58. Based on the distribution chart, Diagnostic Medical Systems ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Diagnostic Medical Systems has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diagnostic Medical Systems' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Diagnostic Medical Systems ranks #999999 out of 473 companies for EV-to-EBIT. This places Diagnostic Medical Systems in the lower half of its industry. The industry median EV-to-EBIT is 19.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.04, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diagnostic Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostic Medical Systems's current EV-to-EBIT is -21.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostic Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Diagnostic Medical Systems (FRA:DMS1) is currently considered Fairly Valued. The stock's GF Value™ is €0.98, compared to a current price of €0.99 — trading 0.6% above its estimated fair value. The current EV-to-EBIT is -21.58. Diagnostic Medical Systems' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Diagnostic Medical Systems (FRA:DMS1), the current EV-to-EBIT is -21.58 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnostic Medical Systems (FRA:DMS1) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnostic Medical Systems stock appears to be overvalued.
The current stock price of €0.99 is trading 0.6% above its estimated GF Value™ of €0.98.
GuruFocus considers Diagnostic Medical Systems to be Fairly Valued.
Key valuation signals for FRA:DMS1:
EV-to-EBIT: -21.58
GF Value™: €0.98 vs. price of €0.99 (0.6% above fair value)
No single metric tells the full story. See the FRA:DMS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
57GF Score
Get the complete analysis for FRA:DMS1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMS1 has been successfully added to your 
